WASHINGTON, DC, August 2, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today announced the initial slate of companies selected to present at its upcoming three-day Cell & Gene Meeting on the Mesa annual conference, October 5-7, 2016.
More than 60 prominent publicly traded and emerging private companies will present at this year’s Partnering Forum, held October 5-6, highlighting clinical and commercial progress in the field. Presenting companies represent the full breadth of this sector, including those active in cell therapy, gene and gene-modified cell therapy, tissue engineering and biomaterials and more. In addition to their presentations, representatives from these organizations will also be available for one-on-one partnering opportunities throughout the conference.
Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is three-day conference featuring three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
Initial slate of presenting companies:
4D Molecular Therapeutics; Abeona Therapeutics; Adverum Biotechnologies; AGTC; Argos Therapeutics; Avita Medical; Biostage; bluebird bio; Caladrius Biosciences; Calimmune; Capricor Therapeutics; Celixir Limited; Cells for Cells; Celyad; Commence Bio; Cryoport Systems; CTI Clinical Trial & Consulting Services; Dimension Therapeutics; DiscGenics; Editas Medicine; GenVec; Histogenics; Immusoft; Intellia Therapeutics; InVivo Therapeutics; Irvine Scientific; Kiadis Pharma; Lysogene; MaxCyte; MEDIPOST America; Mesoblast; MolMed; Nohla Therapeutics; Orchard Therapeutics; Organovo; ORIG3N; Osiris Therapeutics; Oxford BioMedica; Pluristem Therapeutics; Precision Biosciences; Promethera Biosciences; Regencor; Regeneus; ReNeuron Group; Sangamo BioSciences; SCM Lifescience Co.; Scottish National Blood Transfusion Service; Stem Cell & Device Laboratory; StemBioSys; Synpromics; Terumo BCT; TiGenix; ToolGen; TxCell; Universal Cells; Vericel Corporation; ViaCyte; Vitruvian Networks; Voyager Therapeutics
Additions to the list above, as well as a detailed agenda and company presentation times, will be released closer to the event date.
For further event details, please visit www.meetingonthemesa.com.
Registration is currently open, with discounted early-bird rates available through August 26. Registration is complimentary for investors and credentialed members of the media. To learn more and to register, please visit www.meetingonthemesa.com. For members of the media interested in attending, please contact ARM’s Senior Director, Communications, Lyndsey Scull at email@example.com.
For interested organizations looking to increase exposure to this field’s top decision-makers via sponsorship, please contact ARM’s Senior Director, Marketing & Events, Laura Parsons at firstname.lastname@example.org for additional information.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
# # #